Clinical Trials on Squamous Cell Carcinoma of the Head and Neck (SCCHN) in United States

Total 2943 results

Exelixis

Recruiting

Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (STELLAR-305)

Head and Neck Squamous Cell Carcinoma

United States
Roswell Park Cancer Institute

Recruiting

Intensive Symptom Surveillance Guided by Machine Learning-Directed Risk Stratification in Patients With Non-Metastatic Head and Neck Cancer, The INSIGHT Trial

Head and Neck Squamous Cell Carcinoma

United States
University of Chicago
Novartis Pharmaceuticals

Terminated

Study in Locally Advanced Squamous Cell Carcinoma of Head and Neck

Head and Neck Cancer

United States
Washington University School of Medicine
Pfizer; The Joseph Sanchez Foundation

Recruiting

Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

HPV-unrelated Head and Neck Squamous Cell Carcinoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Recruiting

Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca (Spark2)

Head and Neck Squamous Cell Carcinoma

United States
Ohio State University Comprehensive Cancer Center
National Comprehensive Cancer Network

Completed

Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
National Cancer Institute (NCI)

Completed

Ixabepilone in Treating Patients With Metastatic or Recurrent Squamous Cell Cancer of the Head and Neck

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
All India Institute of Medical Sciences, New Delhi

Unknown

Accelerated Fractionation Radiotherapy (AFRT) Versus Concurrent Chemoradiotherapy (Crt) In Locally Advanced Head And Neck Squamous Cell Carcinoma

HEAD AND NECK CANCER

India
Presage Biosciences
AstraZeneca

Recruiting

PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, and Sabestomig in HNSCC

Head and Neck Squamous Cell Carcinoma

United States
Novartis Pharmaceuticals

Terminated

Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy

Metastatic Colorectal Cancer | Squamous Cell Carcinoma of Head and Neck (SCCHN)

France, Belgium, Spain, Germany, Italy, Canada, United States
University of California, Davis

Completed

Use of a Non-ICU Specialty Ward For Immediate Post-operative Management of Head and Neck Free Flaps (ICU)

Head and Neck Cancer | Trauma | Head and Neck Squamous Cell Carcinoma | Head and Neck Carcinoma

United States
Inhibrx, Inc.

Recruiting

INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC

Head and Neck Squamous Cell Carcinoma (HNSCC)

United States
National Cancer Institute (NCI)

Completed

S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
Dan Zandberg
Merck Sharp & Dohme LLC

Active, not recruiting

Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

Recurrent Head and Neck Cancer | Carcinoma, Squamous Cell of Head and Neck

United States
Hoffmann-La Roche

Completed

A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer

Spain, France, United Kingdom, Netherlands, Italy
Vinita Takiar
Merck Sharp & Dohme LLC

Completed

A Study of Chemoradiation Plus Pembrolizumab for Locally Advanced Laryngeal Squamous Cell Carcinoma

Head and Neck Cancer

United States
ALX Oncology Inc.
Merck Sharp & Dohme LLC

Recruiting

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States, Korea, Republic of, United Kingdom, Spain, Belgium, Singapore, Canada, Netherlands, Australia
University of Missouri-Columbia

Recruiting

Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer (ENID)

Oropharynx Cancer | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Cancer of the Head and Neck | Throat Carcinoma

United States
Oncolytics Biotech

Completed

Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Head and Neck Carcinoma

Carcinoma, Squamous Cell of the Head and Neck

United States
M.D. Anderson Cancer Center
Cancer Prevention Research Institute of Texas

Recruiting

Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer

Squamous Cell Carcinoma of the Larynx | Malignant Neoplasms of Respiratory and Intrathoracic Organs

United States
Presage Biosciences
Takeda

Completed

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC

Head and Neck Squamous Cell Carcinoma

United States
University of Chicago
National Cancer Institute (NCI)

Completed

PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
Rakuten Medical, Inc.
National Cancer Institute (NCI); Shimadzu Corporation

Recruiting

ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer

Head and Neck Cancer | Squamous Cell Carcinoma of Head and Neck

United States
Trisha Wise-Draper
AstraZeneca

Active, not recruiting

Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Head and Neck Cancer | Head and Neck Neoplasms | Metastatic Cancer | Recurrent Head and Neck Cancer

United States
National Cancer Institute (NCI)

Completed

Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer

Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage II Squamous Cell Carcinoma of the Oropharynx | Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity and other conditions

United States
Case Comprehensive Cancer Center

Completed

Intraoperative Placement of Cesium-131 Permanent Interstitial Brachytherapy in Head and Neck Cancer

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States
Royal Marsden NHS Foundation Trust

Completed

A Phase II Study of Parotid-gland Sparing IMRT in Patients With Midline Tumour of the Head and Neck (PARSPORT-II)

Oropharyngeal Squamous Cell Cancer | Hypopharyngeal Squamous Cell Cancer

United Kingdom
GlaxoSmithKline

Completed

Phase 2 Study of GSK1363089 (Formerly XL880) in Adults With Squamous Cell Cancer of the Head and Neck

Neoplasms, Head and Neck

United States
AstraZeneca

Completed

IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma

Neoplasms, Squamous Cell

United States, Czech Republic, Poland, Germany, Belgium, Taiwan, India, Serbia
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
European Organisation for Research and Treatment...
Merck KGaA, Darmstadt, Germany

Recruiting

Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma (RAVINA)

Locally Advanced Head and Neck Squamous Cell Carcinoma

France, Belgium, Netherlands, Norway, United Kingdom, Ireland, Italy, Slovenia, Germany, Spain
Emory University
Bristol-Myers Squibb; National Cancer Institute (NCI); The Cleveland Clinic; National... and other collaborators

Active, not recruiting

Intensity-Modulated Radiation Therapy & Nivolumab for Recurrent or Second Primary Head & Neck Squamous Cell Cancer

Recurrent Head and Neck Squamous Cell Carcinoma

United States
Bristol-Myers Squibb

Withdrawn

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

Head and Neck Cancer

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Paclitaxel and Carboplatin Before Radiation Therapy With Paclitaxel in Treating HPV-Positive Patients With Stage III-IV Oropharynx, Hypopharynx, or Larynx Cancer

Human Papilloma Virus Infection | Stage III Squamous Cell Carcinoma of the Hypopharynx | Stage III Squamous Cell Carcinoma of the Larynx | Stage III Squamous Cell Carcinoma of the Oropharynx | Stage III Verrucous Carcinoma of the Larynx | Stage IV Squamous Cell Carcinoma of the Hypopharynx | Stage... and other conditions

United States
Guy's and St Thomas' NHS Foundation Trust

Recruiting

SOTO: Treatment Sensitivity of Organoids to Predict Treatment Outcome

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United Kingdom
Ascendis Pharma Oncology Division A/S

Recruiting

TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma (BelieveIT-201)

Head and Neck Neoplasms

United States, Spain, Georgia, Hungary, Germany, Italy, Taiwan
Medical University of South Carolina

Completed

Building a Renewed ImaGe After Head & Neck Cancer Treatment (BRIGHT)

Head and Neck Squamous Cell Carcinoma | Body Image Disturbance

United States
Roswell Park Cancer Institute

Recruiting

CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer

Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Recurrent Head and Neck Squamous... and other conditions

United States
University of Colorado, Denver
Vasgene Therapeutics, Inc

Completed

sEphB4-HSA With RT+Chemo or Cetux in Patients With Intermediate to High Risk LAHNSCC

Squamous Cell Carcinoma of Head and Neck

United States
AVEO Pharmaceuticals, Inc.

Recruiting

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma (FIERCE-HN)

Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma

United States, Australia, Canada, United Kingdom
Donald T. Weed, MD, FACS

Completed

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States
Abramson Cancer Center at Penn Medicine

Recruiting

Shortened Course Adjuvant Radiotherapy Following TORS

Oropharyngeal Squamous Cell Carcinoma

United States
Alentis Therapeutics AG

Recruiting

Study of ALE.C04 in Patients With Head and Neck Cancer

Head and Neck Cancer | Head and Neck Squamous Cell Carcinoma

United States, Hong Kong, Singapore, Spain, Canada, Italy
Stanford University
National Cancer Institute (NCI); Agennix

Terminated

Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer

Tongue Cancer | Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Recurrent Salivary Gland Cancer | Recurrent Squamous Cell Carcinoma of the Hypopharynx | Recurrent Squamous Cell Carcinoma of the Larynx | Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity | Recurrent Squamous... and other conditions

United States
RTOG Foundation, Inc.
Merck Sharp & Dohme LLC

Recruiting

SBRT +/- Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma (KEYSTROKE)

Head and Neck Squamous Cell Carcinoma (HNSCC)

Canada, United States
Washington University School of Medicine
Eli Lilly and Company

Recruiting

Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma (Rambro2)

Recurrent Head and Neck Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | HNSCC | Recurrent Head and Neck Cancer | Metastatic Head and Neck Cancer | Metastatic Head-and-neck Squamous-cell Carcinoma

United States
NanoCarrier Co., Ltd.

Completed

NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Carcinoma, Squamous Cell of Head and Neck

United States, Hungary, Romania, Bulgaria
Celldex Therapeutics

Terminated

A Study of CDX-3379 and Cetuximab and in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Advanced Head and Neck Squamous Cell Carcinoma

United States
GlaxoSmithKline

Not yet recruiting

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)

Neoplasms, Head and Neck

United States, Taiwan, Mexico, Belgium, Sweden, Australia, Germany, Canada, Japan, Norway, Portugal, Turkey, United Kingdom, Korea, Republic of, Argentina, Italy, Poland, Romania, Czechia, Hungary, Brazil, France, Greece
University of Texas Southwestern Medical Center

Recruiting

HYPORT: A Phase I/II Study of Hypofractionated Post-operative Radiation Therapy for Head and Neck Cancer

Squamous Cell Carcinoma of Head and Neck

United States

Clinical Trials on Squamous Cell Carcinoma of the Head and Neck (SCCHN) in United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mauritania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations